Develop a Data Reviewer’s Guide Template (referenced in the Technical Conformance Guide) and associated documents to allow up front communications regarding the sponsors interpretation of the Bio-research Monitoring Technical Conformance Guide. Initially, the scope will include the development of the template and then expand to cover the full suite of documents. The current cSDRG and ADRG templates will be considered to avoid unnecessary duplication of content. Therefore, revision of these templates are not in scope.
|Julie Maynard (Johnson & Johnson)||email@example.com|
|Sopan Kaith (Alexion – Astra Zeneca)||firstname.lastname@example.org|
(PHUSE Project Assistant)
|Objectives & Deliverables||Timelines|
Finalisation of full BDRG package (assessing/incorporating comments from public review):
|Publication of BDRG||Q2 2022|
CURRENT STATUS Q3/4 2022
|Bio-research Monitoring Data Reviewers Guide (BDRG) Package||22 June 2022|
|Avinash Reddi Patti||GSK|
|Cathy Michalsky||Teva Pharmaceuticals|
|Chunying Yin||Janssen Research & Development|
|Dmitry Golubovsky||Teva Pharmaceuticals|
|Kathryn Knuckles||Eli Lilly|
|Ke Wang||Bristol Myers Squibb|
|Lisa Zhou||Janssen Research & Development|
|Maggie Lo||Lung Biotechnology PBC|
|Nancy Bauer||Boehringer Ingelheim|
|Santosh Kumar Lingala||Gilead|
|Saritha Bathi||Bristol Myers Squibb|
|Stanley Brill||Janssen Research & Development|
|Todd Rider||Bristol Myers Squibb|
|Yan (Joy) Shen||Pfizer|
FDA drafted the initial Bio-research Monitoring Technical Conformance Guide in December 2017, with an updated version published in July 2020 (https://www.fda.gov/media/85061/download). The guide provides specifications for preparing and submitting the following components in electronic format that are used by FDA for planning of Bio-research Monitoring (BIMO) inspections.
NDA, BLA, and supplemental submissions to FDA require BIMO as a critical part of the electronic application.
There is currently a lack of clarity as each sponsor will have defined their own approach to the generation of this content, especially where there is a need to interpret the Technical Conformance Guide.
This need for interpretation leads to inconsistencies between Sponsors when submitting this content to the agency. Potentially, this results in the need for Sponsors to provide additional clarification to the agency subsequent to the submission of the content.